TC BioPharm shares are trading higher after the company announced the execution of a non-binding letter of intent to acquire a company pursuing the development of innovative CAR-T therapies for the treatment of refractory cancers and solid tumors.
$TCBP
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
TC BioPharm shares are trading higher after the company announced the execution of a non-binding letter of intent to acquire a company pursuing the development of innovative CAR-T therapies for the treatment of refractory cancers and solid tumors.